MYLK and gastric cancer: Other studies have also shown that lncRNAs CERS6-AS1, LINC00511, PCED1B-AS1, LINC00649, NR2F1-AS1, AL139002.1, LINC00265, and MYLK-AS1 might promote the progression of gastric cancer and therefore, have the potential to be novel therapeutic targets for treating gastric cancer [64–71].